The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Open accessAbstract
Background Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens.Methods In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m(2) per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation). Patients were stratified by French-American-British and international prognostic scoring system classifications; randomisation was done with a block size of four. The primary endpoint was overall survival. Efficacy analyses were by intention to treat for all patients assigned to receive treatment. This study is registered with ClinicalTrials.gov, number NCT00071799.Findings Between Feb 13, 2004, and Aug 7, 2006, 358 patients were randomly assigned to receive azacitidine (n=179) or conventional care regimens (n=179). Four patients in the azacitidine and 14 in the conventional care groups received no study drugs but were included in the intention-to-treat efficacy analysis. After a median follow-up of 21.1 months (IQR 15.1-26.9), median overall survival was 24.5 months (9.9-not reached) for the azacitidine group versus 15.0 months (5.6-24.1) for the conventional care group (hazard ratio 0.58; 95% CI 0.43-0.77; stratified log-rank p=0.0001). At last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. At 2 years, on the basis of Kaplan-Meier estimates, 50.8% (95% CI 42.1-58.8) of patients in the azacitidine group were alive compared with 26.2% (18.7-34.3) in the conventional care group (p<0.0001). Peripheral cytopenias were the most common grade 3-4 adverse events for all treatments.Interpretation Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypomethylating agents (HMAs), such as azacitidine and decitabine, yield statistically similar complete remission (CR) rates of approximately 15%-20% in patients with either TP53-mutant or wild-type MDS.12-14”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adverse events were similar to those reported for azacitidine or eprenetapopt monotherapy, with the most common grade ≥ 3 adverse events being febrile neutropenia (33%), leukopenia (29%), and neutropenia (29%).”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“Whilst response rates of up to 60% to azacytidine have been reported in MDS 125,129 ,”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationProposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619
Self-citationHarris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Müller‐Hermelink, H. K., Vardiman, J. W., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,261
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D. A., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,814
Self-citationGreenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,625
Self-citationProposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb02771.x · Cited by 1,275
Self-citationModes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
Stresemann, C., & Lyko, F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23607 · Cited by 974
Cheson, B. D., Bennett, J. M., Kantarjian, H. M., Pinto, A., Schiffer, C. A., Nimer, S. D., Löwenberg, B., Beran, M., de Witte, T. M., Stone, R. M., et al. (2000) · PubMed · Cited by 666
Self-citationBurnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608
Valent, P., Horny, H., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P. L., Haferlach, T., Haase, D. T., Kölb, H.-J., Krieger, O., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2006.11.009 · Cited by 514
Self-citationGore, S. D., Baylin, S. B., Sugar, E. A., Carraway, H. E., Miller, C. B., Carducci, M. A., Grever, M. R., Galm, O., Dauses, T., Karp, J. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0080 · Cited by 478
Self-citationGuidelines for the diagnosis and therapy of adult myelodysplastic syndromes
Bowen, D., Culligan, D. J., Jowitt, S. N., Kelsey, S. M., Mufti, G. J., Oscier, D. G., Parker, J., & of the UK MDS Guidelines Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.03907.x · Cited by 300
Self-citationJabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2005) · Blood · doi:10.1182/blood.v106.11.1846.1846 · Cited by 183
Alessandrino, E. P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L. N., Locatelli, F., Marchetti, M., Morra, E., Rebulla, P., et al. (2002) · PubMed · Cited by 178
Estey, E. H., Thall, P. F., Cortes, J. E., Giles, F. J., O'Brien, S. M., Pierce, S. A., Wang, X., Kantarjian, H. M., & Beran, M. (2001) · Blood · doi:10.1182/blood.v98.13.3575 · Cited by 164
Raj, K. K., John, A. M., Ho, A. Y. L., Chronis, C., Khan, S. N., Samuel, J., Pomplun, S., Thomas, N. S. B., & Mufti, G. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404796 · Cited by 146
Self-citationList, A. F., Vardiman, J. W., Issa, J. J., & deWitte, T. (2004) · Hematology · doi:10.1182/asheducation-2004.1.297 · Cited by 120
Self-citationGajewski, J., Ho, W. G., Nimer, S. D., Hirji, K. F., Gekelman, L., Jacobs, A. D., & Champlin, R. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1637 · Cited by 117
Knipp, S., Hildebrand, B., Kündgen, A., Giagounidis, A. A. N., Kobbe, G., Haas, R. R., Aul, C., Gattermann, N., & Germing, U. (2007) · Cancer · doi:10.1002/cncr.22779 · Cited by 115
Self-citationMiller, K. B., Kyungmann, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., & O'Connell, M. J. (1993) · Annals of Hematology · doi:10.1007/bf01697631 · Cited by 114
Self-citationMiller, K. B., Kyungmann, K., Morrison, F. S., Winter, J. N., Bennett, J. M., Neiman, R. S., Head, D. R., Cassileth, P. A., & O'Connell, M. J. (1992) · Annals of Hematology · doi:10.1007/bf01703109 · Cited by 113
Self-citationKantarjian, H. M., Beran, M., Cortes, J. E., O'Brien, S. M., Giles, F. J., Pierce, S. A., Shan, J., Plunkett, W. K., Keating, M. J., & Estey, E. H. (2006) · Cancer · doi:10.1002/cncr.21699 · Cited by 98
Hellström‐Lindberg, E., Robèrt, K., Gahrton, G., Lindberg, G., Forsblom, A., Kock, Y., & Öst, Å. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb02982.x · Cited by 76
Cheson, B. D., & Simon, R. M. (1987) · PubMed · Cited by 68
Hypomethylation and apoptosis in 5-azacytidine–treated myeloid cells
Khan, R., Schmidt‐Mende, J., Karimi, M., Gogvadze, V. G., Hassan, M., Ekström, T. J., Zhivotovsky, B., & Hellström‐Lindberg, E. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2007.10.002 · Cited by 65
Hofmann, W.-K., Heil, G., Zander, C., Wiebe, S., Ottmann, O. G., Bergmann, L., Hoeffken, K., Fischer, J. T., Knuth, A. K., Kolbe, K., et al. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0889-0 · Cited by 57
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome
Barrett, A. J., & Savani, B. N. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.10.005 · Cited by 35
Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes
Cheson, B. D. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00039-3 · Cited by 31
Myelodysplastic Syndromes: Introduction
Sloand, E. M. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.11.008 · Cited by 24
Verbeek, W., Wormann, B. J., Koch, P., Aul, C., Hinrichs, H., Balleisen, L., Rowe, J. M., Bennett, J., Büchner, T., & Hiddemann, W. (1997) · Annals of Hematology · doi:10.1007/s002770050285 · Cited by 23
Self-citationStraaten, H. M., van Biezen, A., Brand, R., Schattenberg, A. V. M. B., Rm, E., Barge, R. M. Y., Cornelissen, J. J., Schouten, H. C., Ossenkoppele, G. J., & Verdonck, L. F. (2005) · PubMed · Cited by 23
Detourmignies, L., Wattel, E., Laı̈, J. L., Bauters, F., & Fenaux, P. (1993) · Annals of Hematology · doi:10.1007/bf01738471 · Cited by 16
Self-citationPrébet, T., Ducastelle, S., Debotton, S., Stamatoullas, A., Deconinck, É., Fruchart, C., Gratecos, N., Ifrah, N., Dreyfus, F., Fenaux, P., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200363 · Cited by 7
Self-citationField, T. L., Perkins, J., Alsina, M., Ayala, E., Fernandez, H. F., Janssen, W. E., Kharfan‐Dabaja, M. A., Lancet, J., Perez, L. E., Sullivan, D. M., et al. (2006) · Blood · doi:10.1182/blood.v108.11.3664.3664 · Cited by 7
Self-citation
Cited by
Sorted by citations
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,900
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citationCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Greenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,625
Self-citation
Metadata
- Authors
- Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S. D., Seymour, J. F., Bennett, J. M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C., & Silverman, L. R.
- Affiliations
- Université Sorbonne Paris Nord (FR)
- King's College Hospital (GB)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University Hospital Schleswig-Holstein (DE)
- Düsseldorf University Hospital (DE)
- Hospital Universitari i Politècnic La Fe (ES)
- Moffitt Cancer Center (US)
- Johns Hopkins University (US)
- Karolinska University Hospital (SE)
- University of Rochester Medicine (US)
- The Ohio State University (US)
- Celgene (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Fenaux, Pierre
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 10
- Issue
- 3
- Pages
- 223-232
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC4086808
- OpenAlex
- W2118771330
- Cited by
- 2,663
- References
- 45
- Citations by year
- 2026: 80 · 2025: 99 · 2024: 103 · 2023: 153 · 2022: 149 · 2021: 182 · 2020: 148 · 2019: 149 · 2018: 132 · 2017: 164 · 2016: 178 · 2015: 173 · 2014: 201 · 2013: 182 · 2012: 178
- FWCI
- 124.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Celgene
- National Cancer Institute (K24CA111717)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- azacitidine, myelodysplastic syndrome, high-risk myelodysplastic syndrome, overall survival, low-dose cytarabine, intensive chemotherapy, best supportive care, hypomethylating agents, treatment efficacy comparison, hematologic malignancies
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Azacitidine, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
